Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia.
Journal: Cancer research communications
Published: May 02, 2024
The AKT inhibitor AZD5363 elicits synthetic lethality in ARID1A-deficient gastric cancer cells via induction of pyroptosis.
Journal: British journal of cancer
Published: July 03, 2023
Exploiting the Receptor-Binding Domains of R-Spondin 1 to Target Leucine-Rich Repeat-Containin G-Coupled Protein Receptor 5-Expressing Stem Cells in Ovarian Cancer.
Journal: The Journal of pharmacology and experimental therapeutics
Published: November 02, 2022
Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma.
Journal: PloS one
Published: October 17, 2022
Luxeptinib disables NLRP3 inflammasome-mediated IL-1β release and pathways required for secretion of inflammatory cytokines IL-6 and TNFα.
Journal: Biochemical pharmacology
Published: October 14, 2021
Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia.
Journal: Molecular cancer therapeutics
Published: October 11, 2021
Single-cell characterization of step-wise acquisition of carboplatin resistance in ovarian cancer.
Journal: NPJ systems biology and applications
Published: July 06, 2021
Therapeutic Targeting of Tumor Cells Rich in LGR Stem Cell Receptors.
Journal: Bioconjugate chemistry
Published: January 25, 2021
WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer.
Journal: Anticancer research
Published: August 21, 2020
Securing the Payload, Finding the Cell, and Avoiding the Endosome: Peptide-Targeted, Fusogenic Porous Silicon Nanoparticles for Delivery of siRNA.
Journal: Advanced materials (Deerfield Beach, Fla.)
Published: May 08, 2019
Tumor Retention of Enzyme-Responsive Pt(II) Drug-Loaded Nanoparticles Imaged by Nanoscale Secondary Ion Mass Spectrometry and Fluorescence Microscopy.
Journal: ACS central science
Published: July 09, 2018
APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells.
Journal: Molecular cancer therapeutics
Published: December 04, 2017
Last Updated: 09/26/2026